Drug Profile
Research programme: antibacterials - Defense Threat Reduction Agency/GlaxoSmithKline/Wellcome Trust
Alternative Names: GSK 299423Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Defense Threat Reduction Agency; GSK
- Class
- Mechanism of Action Type II bacterial DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-negative infections; Nosocomial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Gram-negative-infections in USA (IV)
- 04 Nov 2017 No recent reports of development identified for research development in Nosocomial-infections in USA (IV)
- 26 Mar 2009 Early research development is ongoing in the USA